Answers are grounded in this paper and cite their sources.
Given the scarcity of data available on Plasmablastic lymphoma (PBL) and human immunodeficiency virus (HIV) patients undergoing allogeneic hematopoietic stem cell transplant (Allo-HSCT), we share our experience. We review the barriers overcome by the patient with regards to their diagnosis, treatment, and transplant. We describe challenges encountered when considering Allo-HSCT persons with HIV and PBL. Most significant to the patient was the use of a donor with HIV resistant mutation, homozygous CCR5Δ32/Δ32. Therefore, we pursued transplant with a mismatched unrelated donor (MMUD) to meet patient's desire of a possible HIV cure. We explore the unique approaches and difficulties in treating PBL. Despite post-transplant complications, including early relapse, patient achieved complete remission (CR) by day+100 with a preserved donor graft and undetected viral loads nearing the one-year milestone.
No takes yet. Share an insight, caveat, or question.
Ruiz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: